Cargando…
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
INTRODUCTION: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a common cancer with poor survival outcomes. Although treatment options are limited, real-world treatment patterns and outcomes are not well understood, particularly beyond first-line treatment. This study described real-world trea...
Autores principales: | King, Gentry, Ittershagen, Stacie, He, Luyang, Shen, Ying, Li, Frank, Villacorta, Reginald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618512/ https://www.ncbi.nlm.nih.gov/pubmed/36197644 http://dx.doi.org/10.1007/s12325-022-02317-9 |
Ejemplares similares
-
Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
por: Blomstrand, Hakon, et al.
Publicado: (2020) -
Comparative Proteomic Profiling of Pancreatic Ductal Adenocarcinoma Cell Lines
por: Kim, Yikwon, et al.
Publicado: (2014) -
Efficacy and safety of second-line nab-paclitaxel plus gemcitabine
after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal
adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020) -
PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma
por: Zeleniak, Ann E., et al.
Publicado: (2017) -
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)